PEX5L and major depressive disorder: Several groups have suggested that the TRIP8b–HCN interaction may be a therapeutic target for the treatment of MDD (8, 12, 41) and the development of compounds such as NUCC-0200590 may lead to mechanistically distinct antidepressants.